Biomarker determination via molecular profile assessment and/or NanoString®-based characterization is ongoing to define specific populations of patients with cancer and BRCA1/2 wild-type gene expression for evidence of further sensitivity or resistance to Vigil. This evidence concerns the gene BRCA1 and cancer.